Bernard Zovighian

Bernard Zovighian became CEO of Edwards Lifesciences in 2024, taking over from Michael Mussallem who had led the company for over two decades. Zovighian, who previously served as Edwards' corporate vice president overseeing the transcatheter mitral and tricuspid therapies (TMTT) division, inherited a company that dominates the global market for transcatheter aortic valve replacement (TAVR) — one of the most transformative medical device innovations of the 21st century. Edwards Lifesciences pioneered the TAVR procedure, which allows replacement of a diseased aortic heart valve through a catheter rather than open-heart surgery. The SAPIEN valve platform has been implanted in over a million patients globally. Originally approved only for patients too frail for surgery, TAVR has progressively expanded to moderate-risk and low-risk patients, dramatically increasing the addressable market. Zovighian's key strategic priorities include expanding TAVR adoption into younger, lower-risk patient populations (which requires proving long-term valve durability), advancing Edwards' transcatheter mitral and tricuspid valve programs, growing the critical care monitoring portfolio, and navigating competitive pressure from Medtronic and Abbott in the structural heart space. His decisions on clinical trial investments, new product launches, pricing strategy, and geographic expansion — particularly in underpenetrated markets like China and India — are the primary drivers of Edwards' stock trajectory.